On Flat Q3 Sales, Combimatrix Continues to Explore Strategies | GenomeWeb

NEW YORK (GenomeWeb News) – CombiMatrix reported after the close of the market on Wednesday that its third-quarter revenues slipped around 4 percent year over year, with the decline coming mainly from soft government contracts and product sales.

CombiMatrix brought in total revenues of $970,000 for the three-month period ended Sept. 30, compared to $1 million in the year-ago period.

Revenues for the Mukilteo, Wash.-based company from government contracts fell to $133,000 from $343,000, while revenues from products sales rose to $250,000 from $158,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.